Free Trial

CureVac (CVAC) Stock Price, News & Analysis

-0.09 (-2.58%)
(As of 04:16 PM ET)
Today's Range
50-Day Range
52-Week Range
690,372 shs
Average Volume
799,968 shs
Market Capitalization
$761.19 million
P/E Ratio
Dividend Yield
Price Target

CureVac MarketRank™ Stock Analysis

Analyst Rating
2.00 Rating Score
149.5% Upside
$8.33 Price Target
Short Interest
4.79% of Float Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.82mentions of CureVac in the last 14 days
Based on 2 Articles This Week
Insider Trading
Proj. Earnings Growth
From ($0.84) to ($0.60) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.52 out of 5 stars

Medical Sector

275th out of 918 stocks

Pharmaceutical Preparations Industry

124th out of 429 stocks

CVAC stock logo

About CureVac Stock (NASDAQ:CVAC)

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company also develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

CVAC Stock Price History

CVAC Stock News Headlines

CureVac (NASDAQ:CVAC) Shares Gap Up to $3.48
CureVac Full Year 2023 Earnings: Misses Expectations
CureVac N.V. (CVAC) Q4 2023 Earnings Call Transcript
CureVac appoints new Chief Business Officer
CureVac reports Q4 results
CureVac BV reports Q4 results
CureVac (CVAC) Gets a Buy from Leerink Partners
CureVac, MD Anderson team up for cancer vaccines
See More Headlines
Receive CVAC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CureVac and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
5 Analysts


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$58.18 million
Book Value
$2.50 per share


Free Float
Market Cap
$747.76 million
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Alexander Zehnder M.B.A. (Age 54)
    M.D., CEO, MD & Member of Management Board
    Comp: $1.05M
  • Mr. Pierre Kemula B.Sc. (Age 49)
    MD, CFO & Member of Management Board
    Comp: $700.97k
  • Dr. Malte Greune Ph.D. (Age 59)
    COO, Member of Management Board & MD
    Comp: $643.71k
  • Dr. Myriam Mendila M.D. (Age 58)
    Chief Development Officer, MD & Member of the Management Board
    Comp: $658.44k
  • Dr. Ulrike Gnad-Vogt M.D. (Age 51)
    Ph.D., Senior VP & Area Head of Oncology
    Comp: $304.47k
  • Dr. Sarah Fakih
    Vice President Corporate Communications & Investor Relations
  • Mr. Marco Rau L.L.M.
    Ph.D., General Counsel
  • Mr. Thorsten Schuller
    Head of Corporate Communications
  • Slavica Stevanovic-Heck
    Head of Human Resources
  • Dr. Patrick Baumhof
    Senior Vice President of Technology

CVAC Stock Analysis - Frequently Asked Questions

Should I buy or sell CureVac stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CureVac in the last year. There are currently 1 sell rating, 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" CVAC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CVAC, but not buy additional shares or sell existing shares.
View CVAC analyst ratings
or view top-rated stocks.

What is CureVac's stock price target for 2024?

5 brokers have issued 12-month price objectives for CureVac's stock. Their CVAC share price targets range from $4.00 to $13.00. On average, they anticipate the company's share price to reach $8.33 in the next twelve months. This suggests a possible upside of 149.5% from the stock's current price.
View analysts price targets for CVAC
or view top-rated stocks among Wall Street analysts.

How have CVAC shares performed in 2024?

CureVac's stock was trading at $4.21 at the beginning of the year. Since then, CVAC shares have decreased by 20.7% and is now trading at $3.34.
View the best growth stocks for 2024 here

When is CureVac's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, June 4th 2024.
View our CVAC earnings forecast

How were CureVac's earnings last quarter?

CureVac (NASDAQ:CVAC) issued its quarterly earnings data on Wednesday, April, 24th. The company reported ($0.42) earnings per share (EPS) for the quarter. The company had revenue of $24.30 million for the quarter. CureVac had a negative net margin of 483.81% and a negative trailing twelve-month return on equity of 41.85%.

What ETFs hold CureVac's stock?

ETFs with the largest weight of CureVac (NASDAQ:CVAC) stock in their portfolio include Morningstar US Small Growth (MSGR).Amplify Treatments, Testing and Advancements ETF (GERM).

What other stocks do shareholders of CureVac own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CureVac investors own include Moderna (MRNA), Tesla (TSLA), Novavax (NVAX), Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Pfizer (PFE), Johnson & Johnson (JNJ), Zoom Video Communications (ZM) and NIO (NIO).

When did CureVac IPO?

CureVac (CVAC) raised $200 million in an IPO on Friday, August 14th 2020. The company issued 13,300,000 shares at a price of $14.00-$16.00 per share. BofA Securities, Jefferies and Credit Suisse served as the underwriters for the IPO and Berenberg and Kempen were co-managers.

Who are CureVac's major shareholders?

CureVac's stock is owned by a variety of institutional and retail investors. Top institutional investors include RA Capital Management L.P. (0.88%), Platinum Investment Management Ltd. (0.28%), Tidal Investments LLC (0.03%), China Universal Asset Management Co. Ltd. (0.02%), Ballentine Partners LLC (0.01%) and Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of CureVac?

Shares of CVAC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CVAC) was last updated on 5/20/2024 by Staff

From Our Partners